Loading
companiesCompany
Poseida Therapeutics
Poseida developed off-the-shelf CAR T-cell therapies made from healthy donor cells rather than from each patient, for multiple myeloma and B-cell cancers. Roche bought the company in early 2025 for up to about $1.5 billion.
Overview
Poseida Therapeutics was a clinical-stage company pioneering donor-derived (allogeneic) CAR T-cell therapies, with non-viral piggyBac gene engineering and manufacturing capabilities. Lead programme P-BCMA-ALLO1 is an allogeneic BCMA-directed CAR T for relapsed or refractory multiple myeloma with RMAT and Orphan Drug designations. P-CD19CD20-ALLO1 is a phase 1 allogeneic dual CAR T in B-cell malignancies, also being investigated in multiple sclerosis and lupus, and P-MUC1C-ALLO1 is a phase 1 allogeneic CAR T in solid tumours. Several programmes were already partnered with Roche under a 2022 collaboration. Roche agreed in November 2024 to acquire Poseida for $9.00 per share in cash plus a contingent value right worth up to $4.00 per share, a total of up to about $1.5 billion, and the merger closed on 8 January 2025. Legacy programmes continue within Genentech and the former Nasdaq ticker PSTX was retired.
Headquarters
San Diego, CA, US
Funding
All startupsAcquiredAcquired by Roche / Genentech
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · $9.00 per share in cash (about $1.0 billion equity value) plus a contingent value right of up to $4.00 per share, total deal value up to about $1.5 billion; announced 26 November 2024, completed 8 January 2025 | 2025 | $1.5B | roche.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Acquired
Website
Notes
top- Former Nasdaq ticker PSTX. The CVR portion of the deal value is contingent on milestones.
Similar pages
- IdeaPlan the second CAR-T target before the first one is lost
Shares BCMA, Allogeneic (off-the-shelf) cell therapy, CD20, CD19.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- PersonPolina Stepensky
Shares BCMA, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- CompanyCellogen Therapeutics
Shares CD20, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- TrialStudy of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Shares CD20, CD19, Diffuse large B-cell lymphoma.
- CompanyLEAH Labs
Shares CD20, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- CompanyKelonia Therapeutics
Shares BCMA, CD19, Multiple myeloma.
- CompanyCartesian Therapeutics
Shares BCMA, CAR-T cell therapy, Multiple myeloma.